Anti-IL-17 / VEGF bifunctional fusion protein and uses thereof

The anti-IL-17/VEGF bifunctional fusion protein addresses the limitations of current treatments by simultaneously targeting IL-17 and VEGF pathways, effectively inhibiting their signaling and reducing inflammation and vascular leakage in conditions like psoriasis and diabetic retinopathy.

JP2024544544AInactive Publication Date: 2024-12-03SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527702
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-11
Filing Date
2022-11-10
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for inflammatory diseases such as psoriasis and retinal lesions like diabetic retinopathy and macular degeneration are limited in their ability to simultaneously target IL-17 and VEGF pathways, which are key contributors to these conditions.

Method used

Development of an anti-IL-17/VEGF bifunctional fusion protein that combines an anti-IL-17 antibody with a VEGF-binding protein, such as the extracellular region of VEGFR1, to inhibit both pathways simultaneously.

Benefits of technology

The bifunctional fusion protein effectively binds to IL-17 and VEGF, inhibiting their signaling and reducing associated inflammatory responses and vascular leakage, demonstrating therapeutic potential in treating psoriasis and retinal diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544544000007
    Figure 2024544544000007
  • Figure 2024544544000008
    Figure 2024544544000008
  • Figure 2024544544000009
    Figure 2024544544000009
Patent Text Reader

Abstract

The present invention relates to the technical field of fusion proteins, in particular to an anti-IL-17 / VEGF bifunctional fusion protein and its use. The anti-IL-17 / VEGF bifunctional fusion protein comprises an anti-IL-17 antibody and a protein that specifically binds to VEGF. The protein that specifically binds to VEGF is VEGFR. The protein that specifically binds to VEGF is linked to the anti-IL-17 antibody directly or via a connexon. The anti-IL-17 / VEGF bifunctional fusion protein can simultaneously inhibit the signal pathways of IL-17 and VEGF. The anti-IL-17 / VEGF bifunctional fusion protein can be used to manufacture a medicament for treating diseases in which IL-17 and / or VEGF are overexpressed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of fusion proteins, in particular to anti-IL-17 / VEGF bifunctional fusion proteins and uses thereof. [Background technology]

[0002] Interleukin 17 (IL-17) is a type of inflammatory cytokine that is mainly secreted by helper T cells (Th17) and also secreted in small amounts by T cells and innate immune cells such as mast cells and neutrophils. The IL-17 family has six members (A, B, C, D, E, F and A / F) and exists in homo- or heterodimeric forms. The IL-17 receptors include IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE and SEF. Among them, homodimers IL-17A, IL-17F and heterodimers IL-17A / F are the main forms, which act together with IL-17RA and IL-17RC. IL-17A is expressed at extremely low levels under normal physiological conditions. However, under pathological conditions, IL-17A is secreted in large amounts and binds to IL-17R on the cell surface, and is involved in inflammatory reactions by activating downstream signal pathways such as NF-kB and JNK via the signal transduction complex IL-17R-Act1-TRAF6. As a result, IL-17A plays an important role in the pathological reactions of inflammation and autoimmune diseases (e.g., psoriasis and rheumatoid arthritis). Currently, anti-IL-17 monoclonal antibody drugs are considered an important means of treating psoriasis.

[0003] Psoriasis is a common recurrent and inflammatory skin disease, and its three histopathological components are hyperproliferation of keratinocytes (KC), infiltration of inflammatory cells, and neovascularization. Current research has shown that capillary dilation and elongation, increased permeability, and increased number of blood vessels occur in the papillary dermis of psoriasis-related skin lesions. Moreover, it is believed that such changes occur mainly in the postcapillary venules. The first pathological change that occurs in psoriasis is changes in the distribution and formation of blood vessels. In psoriasis patients, abnormally dilated blood vessels are often seen in the skin other than the skin lesions. In addition, research has shown that the expression levels of vascular endothelial growth factor (VEGF) mRNA and protein are significantly increased in the skin lesions of psoriasis patients compared to healthy skin. Therefore, antiangiogenic drugs may be an effective means of treating psoriasis. In addition, drugs that simultaneously target IL-17 and VEGF are likely to have a synergistic therapeutic effect on psoriasis treatment.

[0004] In addition, many studies have shown that the content of IL-17 is significantly increased in diabetic retinopathy, choroidal neovascular disease (CNV) and macular degeneration. In addition, in a laser-induced CNV model, injection of anti-IL-17 or anti-VEGF antibodies can significantly reduce the generation and leakage of new blood vessels. Therefore, drugs that simultaneously target IL-17 and VEGF are expected to become an innovative new treatment for retinal pathologies such as macular degeneration. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide a novel anti-IL-17 / VEGF bifunctional fusion protein capable of simultaneously inhibiting the signal pathways of IL-17 and VEGF. The object of the present invention is further to provide a nucleic acid molecule encoding the bifunctional fusion protein, an expression vector comprising the nucleic acid molecule, a host cell comprising the expression vector, a method for producing the bifunctional fusion protein, a pharmaceutical composition comprising the bifunctional fusion protein, a use of the bifunctional fusion protein or the pharmaceutical composition in the manufacture of a medicament for treating a disease in which IL-17 and / or VEGF are overexpressed, and a method for applying the fusion protein or the pharmaceutical composition to the treatment of a disease in which IL-17 and / or VEGF are overexpressed. [Means for solving the problem]

[0006] To achieve the above objectives, the present invention provides the following technical solutions:

[0007] In a first aspect of the present invention, there is provided an anti-IL-17 / VEGF bifunctional fusion protein comprising an anti-IL-17 antibody and a protein that specifically binds to VEGF, the protein being VEGFR, and the protein that specifically binds to VEGF being linked to the anti-IL-17 antibody directly or via a connexon.

[0008] The VEGFR may be the entire receptor protein or the extracellular domain of the VEGFR.

[0009] In a preferred embodiment, the protein that specifically binds to VEGF is the extracellular domain of VEGFR. Exemplary extracellular domains of VEGFR include the D2 domain or D3 domain of VEGFR1, the D2 domain, D3 domain or D4 domain of VEGFR2, and the D1 domain, D2 domain or D3 domain of VEGFR3.

[0010] In a preferred embodiment, the protein that specifically binds to VEGF is the extracellular domain of VEGFR1.

[0011] In a preferred embodiment, the protein that specifically binds to VEGF is the D2 domain of VEGFR1.

[0012] The anti-IL-17 antibody may be any anti-IL-17 antibody, provided that the antibody is capable of inhibiting or reducing the binding of IL-17 to its ligand. Preferably, the anti-IL-17 antibody is the 608 antibody.

[0013] Specifically, the heavy chain of the anti-IL-17 antibody comprises complementarity determining regions HCDR1 to 3. The amino acid sequence of HCDR1 is as shown in SEQ ID NO:14, and the amino acid sequence of HCDR2 is as shown in SEQ ID NO:15. The light chain of the anti-IL-17 antibody comprises complementarity determining regions LCDR1 to LCDR3. The amino acid sequence of LCDR1 is shown in SEQ ID NO:15, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:16. The amino acid sequence of LCDR2 is as shown in SEQ ID NO:18, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO:19.

[0014] In a preferred embodiment, the amino acid sequence of the heavy chain variable region of the anti-IL-17 antibody is as shown in SEQ ID NO:20, and the amino acid sequence of the light chain variable region of the anti-IL-17 antibody is as shown in SEQ ID NO:21. As shown in ID NO:21.

[0015] In a preferred embodiment, the anti-IL-17 antibody is a monoclonal antibody.

[0016] In a preferred embodiment, the IL-17 antibody is a humanized antibody.

[0017] In a preferred embodiment, the anti-IL-17 antibody is an IgG class antibody, such as a full-length antibody of IgG1, IgG2 or IgG4 type.

[0018] In a preferred embodiment, the amino acid sequence of the heavy chain of the anti-IL-17 antibody is as shown in SEQ ID NO:4, and the amino acid sequence of the light chain is as shown in SEQ As shown in ID NO:1.

[0019] In other embodiments, the anti-IL-17 antibody may be another antibody that binds to IL-17 competitively with the 608 antibody.

[0020] In some specific embodiments of the invention, the anti-IL-17 antibody has a heavy chain amino acid sequence shown in SEQ ID NO:4, or The light chain amino acid sequence shown in ID NO:1 may be based on the light chain amino acid sequence, and may be obtained by substituting, deleting or adding one or more amino acids (specifically, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3). The amino acid sequence after substitution, deletion or addition may be represented by SEQ The nucleic acid may have a degree of similarity of 80%, 85%, 90%, 93%, 95%, 97% or 99% or more to SEQ ID NO:4 or SEQ ID NO:1.

[0021] In one embodiment, the D2 domain of a VEGFR may be wild type or mutant.

[0022] The amino acid sequence of wild-type VEGFR-D2 is shown in SEQ ID NO:34.

[0023] The mutant of the VEGFR D2 domain is obtained by substituting, deleting or adding one or more amino acids (specifically, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3) based on the amino acid sequence shown in SEQ ID NO: 34. The amino acid sequence after substitution, deletion or addition is the same as that shown in SEQ It may have a degree of similarity of 80%, 85%, 90%, 93%, 95%, 97% or 99% or more to ID NO:34.

[0024] In a preferred embodiment, the mutant VEGFR-D2 has a mutation at position 138 of the amino acid sequence shown in SEQ ID NO:34.

[0025] In addition, the mutant VEGFR-D2 has a substitution mutation at position 138 of the amino acid sequence shown in SEQ ID NO:34.

[0026] In addition, the mutant of VEGFR-D2 is selected from 138M / A, 138M / P or 138M / T. These three mutations have unpredictable technical effects, significantly reducing the cleavage of the heavy chain of the fusion protein and improving the acceleration and thermostability.

[0027] In a preferred embodiment, the connexon may have a flexible polypeptide sequence such as (G4S)x, where x may be 1, 2, 3, 4, 5 or 6. In some preferred embodiments, the C-terminus (as shown in FIG. 1A) or N-terminus (as shown in FIG. 1B) of the heavy chain of the anti-IL-17 antibody IgG and a protein that specifically binds to VEGF are linked in tandem to form the heavy chain of a bifunctional fusion protein.

[0028] In some preferred embodiments, the C-terminus (shown in FIG. 1C) or N-terminus (shown in FIG. 1D) of the light chain of the anti-IL-17 antibody IgG and a protein that specifically binds to VEGF are linked in tandem to form the light chain of a bifunctional fusion protein.

[0029] In a preferred embodiment, the C-terminus or N-terminus of the heavy chain of the anti-IL-17 antibody is linked to the D2 domain of VEGFR1, and in another preferred embodiment, the C-terminus or N-terminus of the light chain of the anti-IL-17 antibody is linked to the D2 domain of VEGFR1.

[0030] To reduce shearing of the fusion protein, amino acids at the terminus of the Fc may be mutated, for example, in the Examples, amino acid K at the terminus of the Fc region of human IgG1 is mutated to A.

[0031] In a preferred embodiment, the amino acid sequence of the heavy chain of the bifunctional fusion protein is SEQ ID NO:2, SEQ ID NO:3, SEQ The amino acid sequence of the light chain of the bifunctional fusion protein is as shown in SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10. As shown in SEQ ID NO:1, SEQ ID NO:5 or SEQ ID NO:6.

[0032] In a second aspect of the invention there is provided a nucleic acid molecule, said nucleic acid molecule encoding said fusion protein.

[0033] In a preferred embodiment, the nucleic acid molecule comprises the nucleic acid sequence SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, S 27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 or SEQ ID NO:33; NO:24, SEQ ID NO:28 or SEQ ID NO:29.

[0034] Those skilled in the art are well aware that by appropriately introducing substitutions, deletions, modifications, insertions or additions into a nucleic acid molecule encoding the amino acid sequence of the above-mentioned fusion protein, it is possible to provide a homologue of the nucleic acid molecule.

[0035] In a third aspect of the invention there is provided an expression vector comprising the nucleic acid molecule as defined above.

[0036] In a fourth aspect of the invention there is provided a host cell, said host cell comprising said expression vector.

[0037] In a fifth aspect of the present invention, there is provided a method for producing a bifunctional fusion protein, the method comprising the steps a) and b) of: In step a), the anti-IL-17 / VEGF bifunctional fusion protein is expressed by culturing the host cells described above under expression conditions. In step b), said bifunctional fusion protein of step a) is isolated and purified.

[0038] In a sixth aspect of the present invention, there is provided a pharmaceutical composition comprising an effective amount of the bifunctional fusion protein and one or more pharma- ceutically acceptable carriers or excipients.

[0039] In a seventh aspect of the present invention, there is provided a use of the bifunctional fusion protein or pharmaceutical composition in the manufacture of a medicament for treating a disease in which IL-17 and / or VEGF are overexpressed.

[0040] According to the present invention, the disease in which IL-17 and / or VEGF is overexpressed is selected from inflammatory skin diseases or ophthalmological diseases.

[0041] For example, the inflammatory skin disease is psoriasis. The ophthalmological disease is, for example, diabetic retinopathy, choroidal neovascular disease (CNV) or macular degeneration. The macular degeneration is, for example, wet age-related macular degeneration.

[0042] In an eighth aspect of the present invention, there is provided a use of the bifunctional fusion protein or pharmaceutical composition in the manufacture of a medicament for the treatment of an inflammatory skin disease or an ophthalmological disease.

[0043] For example, the inflammatory skin disease is psoriasis. The ophthalmological disease is, for example, diabetic retinopathy, choroidal neovascular disease (CNV) or macular degeneration. The macular degeneration is, for example, wet age-related macular degeneration.

[0044] When the anti-IL-17 / VEGF bifunctional fusion protein and its pharmaceutical composition of the present invention are administered to animals including humans, the dosage varies depending on the age and weight of the patient, the characteristics and severity of the disease, and the administration route. Therefore, the total dosage should not exceed a certain range, taking into consideration the results of animal experiments and various circumstances. Each preferred embodiment of the present invention can be obtained by arbitrarily combining each of the above preferred conditions based on the common knowledge in the field.

[0045] In a ninth aspect of the present invention, there is provided a method for treating a disease in which IL-17 and / or VEGF are overexpressed, the method comprising administering to a subject in need thereof the bifunctional fusion protein or pharmaceutical composition as described above.

[0046] According to the present invention, the disease in which IL-17 and / or VEGF is overexpressed is selected from inflammatory skin diseases or ophthalmological diseases.

[0047] For example, the inflammatory skin disease is psoriasis. The ophthalmological disease is, for example, diabetic retinopathy, choroidal neovascular disease (CNV) or macular degeneration. The macular degeneration is, for example, wet age-related macular degeneration.

[0048] In a tenth aspect of the present invention, there is provided a method for treating an inflammatory skin disease or an ophthalmological disease, the method comprising administering to a subject in need thereof the bifunctional fusion protein or pharmaceutical composition as defined above.

[0049] For example, the inflammatory skin disease is psoriasis. The ophthalmological disease is, for example, diabetic retinopathy, choroidal neovascular disease (CNV) or macular degeneration. The macular degeneration is, for example, wet age-related macular degeneration. The anti-IL-17 / VEGF bifunctional fusion protein and its pharmaceutical composition should be administered to a subject at a therapeutically effective dose. The therapeutically effective dose is an amount that is effective in treating diseases in which IL-17 and / or VEGF are overexpressed. Specifically, the anti-IL-17 / VEGF bifunctional fusion protein and its pharmaceutical composition should be administered to a subject at a dose that varies depending on the age and weight of the patient, the characteristics and severity of the disease, and the administration route. Therefore, the total dosage should not exceed a certain range, taking into consideration the results of animal experiments and various circumstances.

[0050] In an eleventh aspect of the present invention, there is provided a fusion protein comprising a D2 domain of VEGFR1, wherein the D2 domain of VEGFR1 has a mutation, and wherein the fusion protein has improved stability.

[0051] In a preferred embodiment, the fusion protein further comprises at least one heterologous domain, including but not limited to an antibody, Fc fragment, to improve targeting, stability, toxicity, tumor killing activity, etc.

[0052] In a preferred embodiment, the D2 domain of VEGFR1 has a mutation at position 138 of the amino acid sequence shown in SEQ ID NO:34.

[0053] In addition, the D2 domain of VEGFR1 has a substitution mutation at position 138 of the amino acid sequence shown in SEQ ID NO:34.

[0054] In addition, the D2 domain of VEGFR1 has a mutation of 138M / A, 138M / P or 138M / T. Effect of the Invention

[0055] The positive effects of the present invention are as follows:

[0056] The bifunctional fusion protein of the present invention can bind to IL-17 and VEGF with high affinity. The affinity to IL-17 is equivalent to that of the positive control 608 of anti-IL-17 monoclonal antibody. The fusion protein of the present invention can effectively inhibit the binding of IL-17 receptor to IL-17, and the inhibitory ability is equivalent to that of the positive control 608 of anti-IL-17 monoclonal antibody. The fusion protein of the present invention can effectively inhibit the interaction of VEGF with its receptor KDR, and the inhibitory ability is superior to that of bevacizumab, which is the positive control of anti-VEGF monoclonal antibody. In a drug efficacy test at the cell level, the fusion protein of the present invention can effectively suppress the secretion of IL-6 and VEGF induced by IL-17. In a drug efficacy test at the animal level, the fusion protein of the present invention can effectively treat psoriasis and choroidal neovascularization disease. In summary, the fusion protein of the present invention has potential in the treatment of diseases related to IL-17 and VEGF activity. [Brief description of the drawings]

[0057] [Figure 1A] FIG. 1A is a schematic structural diagram of the bifunctional fusion protein of the present invention, in which the light gray area indicates the variable region, the dark gray area indicates the constant region, and the patterned area indicates the D2 domain of VEGFR1. [Figure 1B] FIG. 1B is a schematic structural diagram of another bifunctional fusion protein of the present invention, in which the light gray area indicates the variable region, the dark gray area indicates the constant region, and the patterned area indicates the D2 domain of VEGFR1. [Figure 1C] FIG. 1C is a schematic structural diagram of another bifunctional fusion protein of the present invention, in which the light gray area indicates the variable region, the dark gray area indicates the constant region, and the patterned area indicates the D2 domain of VEGFR1. [Figure 1D] FIG. 1D is a schematic structural diagram of another bifunctional fusion protein of the present invention, in which the light gray area indicates the variable region, the dark gray area indicates the constant region, and the patterned area indicates the D2 domain of VEGFR1. [Figure 2A] FIG. 2A shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V01 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2B] FIG. 2B shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V02 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2C] FIG. 2C shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V03 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2D] FIG. 2D shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V04 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2E] FIG. 2E shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V05 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2F] FIG. 2F shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V06 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2G] FIG. 2G shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V07 prepared by HPLC measurement in Example 2 of the present invention. [Figure 2H] FIG. 2h shows the purity result of the anti-IL-17 / VEGF bifunctional fusion protein 17V08 prepared by HPLC measurement in Example 2 of the present invention. [Figure 3A] FIG. 3A shows the ELISA measurement of the affinity of the anti-IL-17 / VEGF bifunctional fusion protein to IL-17 in Example 3 of the present invention. [Figure 3B] FIG. 3B shows the ELISA measurement of the affinity of the anti-IL-17 / VEGF bifunctional fusion protein to VEGF in Example 3 of the present invention. [Figure 4]FIG. 4 shows the results of the inhibition of IL-17A-induced IL-6 secretion from HeLa cells by the anti-IL-17 / VEGF bifunctional fusion protein in Example 6 of the present invention. [Diagram 5] FIG. 5 shows the results of the inhibition of the binding of VEGF to its receptor KDR by the anti-IL-17 / VEGF bifunctional fusion protein in Example 7 of the present invention. [Figure 6] FIG. 6 shows the percent change in vascular leakage area in animals after administration of the anti-IL-17 / VEGF bifunctional fusion protein in Example 10 of the present invention. [Figure 7] FIG. 7 shows statistical data of leakage spots of levels 3 to 4 in Example 10 of the present invention. [Figure 8] FIG. 8 shows the results of IB4 immunofluorescence staining after preparation of a choroid in Example 10 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0058] The following experimental examples are provided to further illustrate the present invention and should not be construed as limiting the present invention. In the examples, conventional methods or methods common in the art, such as, for example, methods for preparing nucleic acid molecules, methods for preparing vectors and plasmids, methods for inserting protein-encoding genes into such vectors and plasmids or methods for introducing plasmids into host cells, and methods for culturing host cells, are not described in detail. Such methods are well known to those skilled in the art and are described in many publications, including the following: Sambrook, J., Fritsch, EFand Maniais, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press.

[0059] In the present invention, the term "bifunctional fusion protein" refers to a new polypeptide sequence obtained by fusing two or more identical or different polypeptide sequences. The term "fusion" refers to a direct linkage by peptide bond or an effective linkage via one or more linking peptides (peptide linkers). The term "linking peptide (connexon)" refers to a short peptide capable of linking two polypeptide sequences, generally a peptide having a length of 2 to 30 amino acids.

[0060] In the present invention, the term "antibody (abbreviated as Ab)" includes full-length antibodies and antibody fragments. A "full-length antibody" is a heterotetrameric glycoprotein of about 150,000 daltons with identical structural characteristics, which is composed of two identical light chains (LC) and two identical heavy chains (HC). Each heavy chain has a variable region (VH) at one end, followed by a constant region. The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain has a variable region (VL) at one end, followed by a constant region at the other end. The light chain constant region contains one domain, CL. The light chain constant region and the CH1 domain of the heavy chain constant region are paired, and the light chain variable region and the heavy chain variable region are paired. The constant regions are not directly involved in the binding of the antibody to the antigen, but exhibit different effector functions, such as antibody-dependent cellular cytotoxicity (ADCC). It is involved in inflammatory cell-mediated cytotoxicity (AML) and the like. The heavy chain constant region has subtypes of IgG1, IgG2, IgG3, and IgG4. The light chain constant region has subtypes of κ (Kappa) and λ (Lambda). The heavy and light chains of an antibody are covalently bonded by a disulfide bond between the CH1 domain of the heavy chain and the CL domain of the light chain. The two heavy chains of an antibody are covalently bonded by a disulfide bond between polypeptides formed between the hinge regions. The term "antibody fragment" refers to a functional fragment derived from an antibody and maintaining the ability to bind to an epitope of an antigen, including, but not limited to, scFv, Fv, Fd, Fab, F(ab')2, or F(ab').

[0061] In the present invention, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population; that is, each antibody in the population is identical, except for a small number of naturally occurring mutations that may exist. Monoclonal antibodies target a single antigen site with high specificity. And, unlike typical polyclonal antibody preparations (which are usually mixtures of different antibodies targeting different antigenic determinants), each monoclonal antibody targets a single determinant on the antigen. In addition to specificity, monoclonal antibodies have the advantage that they can be synthesized by hybridoma culture and are therefore not contaminated by other immunoglobulins.

[0062] In the present invention, the term "humanized" means that the CDRs are derived from an antibody of a species other than human (preferably mouse), and the remaining part of the antibody molecule (including the framework and constant regions) is derived from a human antibody, and residues in the framework regions may be altered to maintain binding affinity.

[0063] In the present invention, the terms "antibody" and "binding" refer to a non-random binding reaction between two molecules, for example, a reaction between an antibody and an antigen against which the antibody is targeted. Typically, an antibody is bound to an antigen, for example, at about 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 Less than M or even smaller, e.g., about 10 -7 The antibody binds to the antigen with an equilibrium dissociation constant (KD) of less than M. The term "KD" is the equilibrium dissociation constant of a particular antibody-antigen interaction and is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. For example, surface plasmon resonance (SPR) The binding affinity between an antibody and an antigen is measured using plasmon resonance (SPR) by BIACORE, or the relative affinity of the binding between an antibody and an antigen is measured by ELISA.

[0064] In the present invention, the "D2 domain of VEGFR1" refers to the D2 domain of the extracellular region of VEGFR1, and includes the native sequence and its variants (containing at least one amino acid mutation), as long as the mutated domain maintains its binding activity to VEGF.

[0065] In the present invention, the term "expression vector" refers to a vector comprising an expression cassette for expressing a specific target protein or other substance, such as a plasmid, a viral vector (e.g., adenovirus, retrovirus), a bacteriophage, a yeast plasmid, or other vector. It also refers to an expression vector common in the art, including suitable regulatory sequences such as a promoter, a terminator, an enhancer, etc., and the expression vector may be a viral vector (e.g., adenovirus, retrovirus), a plasmid, a bacteriophage, a yeast plasmid, or other vector. The expression vector preferably includes pDR1, pcDNA3.4(+), pDHFR, or pTT5. Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. For this purpose, the relevant sequence is usually cloned into a vector and then introduced into a cell. The relevant sequence is then isolated and obtained from the host cells after growth in a common manner.

[0066] In the present invention, the term "host cell" refers to various host cells commonly used in the art, and may be any host cell capable of stably replicating a vector and effectively expressing an attached nucleic acid molecule. The host cell includes prokaryotic expression cells and eukaryotic expression cells. The host cell is preferably selected from COS, CHO, NS0, sf9, sf21, DH5α, BL21(DE3), TG1, BL21(DE3), 293F cells, or 293E cells.

[0067] In the present invention, the term "pharmaceutical composition" refers to a composition containing the bifunctional fusion protein and a pharma- ceutical acceptable carrier or additive. Usually, these substances are prepared in a harmless, inert, and pharma- ceutical acceptable aqueous carrier medium. The pH value may vary depending on the nature of the preparation and the disease to be treated, but is usually about pH 4 to 8, preferably about pH 5 to 7. The prepared pharmaceutical composition can be administered by a common route, including (but not limited to) intravenous injection, intravenous drip, subcutaneous injection, local injection, intramuscular injection, intratumoral injection, intraperitoneal injection (e.g., intraperitoneal), intracranial injection, or intracavity injection.

[0068] In the present invention, the term "pharmaceutical composition" refers to a pharmaceutical preparation for more stable therapeutic effect. These preparations can ensure the integrity of the conformation of the amino acid core sequence in the bifunctional fusion protein disclosed in the present invention, and can also protect multiple functional groups of the protein to prevent degradation (including but not limited to aggregation, deamination, or oxidation).

[0069] By "pharmaceutical acceptable" is meant that they do not produce adverse, allergic or other side reactions when administered appropriately to animals or humans.

[0070] A "pharmaceutically acceptable carrier or additive" must be compatible with the active ingredient. That is, even if mixed with the active ingredient, it must not significantly reduce the effect of the drug under normal circumstances. Specific examples of some substances that can be pharmaceutically acceptable carriers or additives include sugars such as lactose, glucose and saccharose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium methylcellulose, ethylcellulose and methylcellulose, tragacanth gum powder, malt, gelatin, talc, solid lubricants such as stearic acid and magnesium stearate, calcium sulfate, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter, polyols such as propanediol, glycerol, sorbitol, mannitol and polyethylene glycol, alginic acid, emulsifiers such as Tween, wetting agents such as sodium lauryl sulfate, colorants, flavorings, tableting agents, stabilizers, diluents, excipients, antioxidants, preservatives, pyrogen-free water, balanced salt solutions, buffers such as phosphate buffers, etc. These substances may aid in the stability of the composition, aid in enhancing activity or bioavailability, or produce an acceptable mouthfeel or flavor upon oral administration, as appropriate.

[0071] The pharmaceutical composition of the present invention comprises a safe and effective amount (for example, 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the bifunctional fusion protein of the present invention and a pharma- ceutical acceptable carrier. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should be adapted to the mode of administration. The pharmaceutical composition of the present invention may be prepared in the form of an injection, for example, by using a saline solution or an aqueous solution containing glucose and other auxiliary agents in a general manner. The pharmaceutical composition such as an injection or solution should be prepared under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 μg / kg body weight to about 50 mg / kg body weight per day. In addition, the bifunctional fusion protein of the present invention may be used in combination with other therapeutic agents.

[0072] In the present invention, the term "effective amount" refers to an amount or dosage that produces a desired effect in a treated individual after administration of the pharmaceutical composition of the present invention to the subject. The desired effect includes improvement of the individual's disease. The term "subject" includes, but is not limited to, humans, non-human primates, and mammals such as rats and mice. In the method of treating a disease that overexpresses IL-17 and / or VEGF in the present invention, the "treatment" or "method of treatment" includes preventing or alleviating any condition, reducing the onset or rate of progression of any condition, reducing the risk of progression of any condition, preventing or slowing the progression of symptoms of any condition, reducing or halting symptoms of any condition, causing complete or partial reversal of any condition, curing any condition, or any combination thereof.

[0073] In some embodiments, the methods described herein may be further performed in combination with other compounds or other treatment regimens in the art. SEQ ID NOs corresponding to the sequences referred to in the Examples below are summarized in Table 6 at the end of this document.

[0074] Example 1 Construction of anti-IL-17 / VEGF bifunctional fusion protein In the present invention, an antibody fusion protein was prepared by tandemly linking the D2 domain of VEGFR1 to the C-terminus (shown in FIG. 1A) or N-terminus (shown in FIG. 1B) of the heavy chain of anti-IL-17 monoclonal antibody (608 monoclonal antibody) IgG, the C-terminus (shown in FIG. 1C) of the light chain, and the N-terminus (shown in FIG. 1D) of the light chain. The 608 monoclonal antibody was obtained from the humanized anti-human IL17A monoclonal antibody in Chinese Patent Application No. 201780033670.5. In addition, the D2 domain of VEGFR1 (amino acids 129 to 227) contained the wild-type D2 domain and a specifically mutated D2 domain. The structure of each fusion protein is described in Table 1.

[0075] [Table 1]

[0076] Example 2 Construction of anti-IL-17 / VEGF bifunctional fusion protein The heavy and light chain DNA fragments of the anti-IL-17 / VEGF bifunctional fusion protein were subcloned into the pcDNA3.4 vector (purchased from Thermo Fisher Scientific, A14697), and the recombinant plasmids were extracted and co-transfected into CHO cells and / or 293F cells. After culturing the cells for 7 days, the culture medium was centrifuged at high speed, vacuum filtered through a microfiltration membrane, and then filtered using a HiTrap The mixture was loaded onto a MabSelect SuRe column. The protein was then eluted in one step using an elution solution of 100 mM citric acid and pH 3.5, and the target sample was collected and dialyzed to exchange the culture medium for PBS. The purified protein was then measured by HPLC. The results are shown in Figures 2A to 2H. The measurement results showed that the molecular state of the fusion protein was homogenous, and the monomer purity after one purification was between 94.0 and 98.9%.

[0077] Example 3 Affinity measurement of anti-IL-17 / VEGF bifunctional fusion protein to antigen by enzyme-linked immunosorbent assay (ELISA)

[0078] 3.1 Measurement of the affinity of anti-IL-17 / VEGF bifunctional fusion protein to IL-17A by ELISA IL-17A protein (purchased from AcroBiosystems, Cat.#ILA-H5118) was coated on the plate at 100ng / well and left at 4℃ overnight. Next, the plate was washed three times with PBST, blocking solution was added at 200μl / well, and left at 37℃ for 1 hour, after which the plate was washed once with PBST and left to stand. In addition, the antibody was diluted to 25nM with diluent, and 8 concentration gradients were formed by 4-fold dilution. This was added to the blocked ELISA plate at 100μl / well and left at 37℃ for 1 hour. Next, the plate was washed three times with PBST, and goat anti-human Fab antibody labeled with HRP (purchased from Abcam, Cat.#ab87422) was added and left at 37℃ for 30 minutes. After washing the plate three times with PBST, the remaining liquid was removed as much as possible with absorbent paper, and 100 μl of TMB was added to each well and left for 5 minutes at room temperature (20 ± 5°C) in the dark. Then, a stop solution was added to each well to stop the reaction of the substrate. Then, the OD value was read at 450 nm with an enzyme-linked immunosorbent assay device, and the results were analyzed using GraphPad. Data analysis was performed using Prism6 to generate graphs and to measure EC 50 was calculated.

[0079] The experimental results are shown in Figure 3A. The anti-IL-17 / VEGF bifunctional fusion proteins 17V01, 17V02, 17V03, and 17V04, as well as the positive control 608 monoclonal antibody, were all able to effectively bind to IL-17A. 50 The (nM) values ​​were 0.052, 0.062, 0.041, 0.105 and 0.052, respectively, indicating comparable affinities.

[0080] 3.2 Measurement of the affinity of anti-IL-17 / VEGF bifunctional fusion protein to VEGF by ELISA To measure the binding ability of the anti-IL-17 / VEGF bifunctional fusion protein to VEGF, VEGF protein (purchased from AcroBiosystems, Cat.#VE5-H4210) was coated on a plate at 100ng / well and left at 4℃ overnight. Next, the plate was washed three times with PBST, blocking solution was added at 200μl / well, and left at 37℃ for 1 hour, after which the plate was washed once with PBST and left waiting. In addition, the antibody was diluted to 25nM with diluent, and 8 concentration gradients were formed by 4-fold dilution. This was added to the blocked ELISA plate at 100μl / well and left at 37℃ for 1 hour. Next, the plate was washed three times with PBST, and goat anti-human Fab antibody labeled with HRP (purchased from Abcam, Cat.#ab87422) was added and left at 37℃ for 30 minutes. After washing the plate three times with PBST, the remaining liquid was removed as much as possible with absorbent paper, and 100 μl of TMB was added to each well and left for 5 minutes at room temperature (20 ± 5°C) in the dark. Then, a stop solution was added to each well to stop the reaction of the substrate. Then, the OD value was read at 450 nm with an enzyme-linked immunosorbent assay device, and the results were analyzed using GraphPad. Data analysis was performed using Prism6 to generate graphs and to measure EC 50 was calculated.

[0081] The experimental results are shown in Figure 3B. The anti-IL-17 / VEGF bifunctional fusion proteins 17V01, 17V02, 17V03, 17V04, and FC-D2 were all able to effectively bind to VEGF. 50 The (nM) values ​​were 0.379, 0.327, 0.326, 0.371 and 0.397, respectively, indicating similar affinities. On the other hand, the anti-IL-17 monoclonal antibody 608 was unable to bind effectively to VEGF.

[0082] Example 4 Measurement of affinity and dissociation constant (KD) of anti-IL-17 / VEGF bifunctional fusion protein for antigen IL-17A The kinetic parameters of binding and dissociation between the anti-IL-17 / VEGF bifunctional fusion protein and the antigen IL-17A were measured by the capture method using a Biacore 8K molecular interaction analyzer. HBS-EP + buffer 17V01, 17V05, 17V06, and 608 were each diluted to 1.5 μg / ml using pH 7.4 (Cat. #BR-1007-69, GE Healthcare) as a dilution buffer. Six concentration gradients were set up with the highest concentration of IL-17A at 12.5 nM, and a zero concentration was also added. A capture antibody bound to a chip A (Cat.#29-1275-56, GE Healthcare) was used. IL-17A was then input as the analyte, and a binding-dissociation curve was obtained. After that, 6M guanidine hydrochloride (Cat.#30095516, purchased from China Pharmaceutical Group Chemical Reagents Co., Ltd.) was used as the regeneration buffer to elute the antibody, and the next cycle was repeated. The data was analyzed by Biacore. Analysis was performed using 8K Evaluation Software.

[0083] The experimental results are shown in Table 2. The anti-IL-17 / VEGF bifunctional fusion proteins 17V01, 17V05, and 17V06 had affinity for IL-17A equivalent to that of the positive control anti-IL-17 monoclonal antibody 608.

[0084] [Table 2]

[0085] Example 5 Measurement of affinity and dissociation constant (KD) of anti-IL-17 / VEGF bifunctional fusion protein for antigen VEGF The binding and dissociation kinetic parameters of the anti-IL-17 / VEGF bifunctional fusion protein and the antigen VEGF were measured by the capture method using a Biacore 8K molecular interaction analyzer. + buffer Bevacizumab, 17V01, 17V05, and 17V06 were diluted to 5 μg / ml with a dilution buffer of pH 7.4. Six concentration gradients were set up with the highest concentration of VEGF at 10 nM, and a zero concentration was also added. A chip was used with bound capture antibody, and VEGF was loaded as the analyte, and the binding-dissociation curve was obtained, then eluted with 6M guanidine hydrochloride as the regeneration buffer, followed by the next cycle. The data was analyzed by Biacore. Analysis was performed using 8K Evaluation Software.

[0086] The experimental results are shown in Table 3. The anti-IL-17 / VEGF bifunctional fusion proteins 17V01, 17V05, and 17V06 had slightly higher affinity for VEGF than the positive control, bevacizumab.

[0087] [Table 3]

[0088] Example 6 Inhibitory effect of anti-IL-17 / VEGF bifunctional fusion protein on IL-17A-induced IL-6 secretion in HeLa cells IL-17A can stimulate epithelial cells to secrete IL-6. Human cervical cancer cell line HeLa was stimulated with 10ng / ml human IL-17A, and clear human IL-6 secretion was measured by ELISA. Using this system, it was possible to measure the level of inhibition of human IL-17A-induced human IL-6 secretion by HeLa. HeLa cells were cultured until the logarithmic phase, and the medium was discarded, digested with pancreatin, centrifuged at 300g for 5 minutes, resuspended, counted, and the density-adjusted cells were seeded into a 96-well microplate. 10000 cells / well, 100μl was added to each well. This was placed in a cell culture device and cultured for 2 hours. Each test sample was diluted with medium to a starting concentration of 40μg / ml, and 10 concentrations were formed by 3-fold dilution. Two wells were set up for each group, and 70μl was taken into a new 96-well microplate. The concentration of IL-17A was also diluted to 40ng / ml using medium, and 70μl was added to the 96-well microplate containing 70μl of diluted antibody. Then, 100μl of the solution was added per well to the inoculated HeLa cells. Thus, the final concentration of the antibody was 10μg / ml, and the final concentration of IL-17A was 10ng / ml. This was then placed in a 37℃ incubator and cultured overnight.

[0089] Rat anti-human IL-6 antibody was diluted to 2.5 μg / ml with coating buffer, added to the ELISA plate at 100 μl / well, and left overnight at 4°C. Next, the plate was washed three times with PBST, blocking solution was added at 200 μl / well, and left at 37°C for 2 hours, after which the plate was washed three times with PBST and left to stand. In addition, an IL-6 standard was prepared. That is, a standard was prepared using culture medium, and the initial concentration was 50 ng / ml. In addition, a total of 12 gradients were formed by diluting it two-fold in sequence. This was added to the coated ELISA plate at 100 μl per well. Note that two wells were provided for each concentration. Next, HeLa cells cultured overnight were mixed evenly, and 100 μl was taken and diluted two-fold with DMEM medium. This was transferred to a new 96-well microplate and centrifuged at 300 g for 5 minutes. Then, 100 μl of the supernatant from each well was taken and added to the ELISA plate, and cultured at room temperature for 1.5 hours. Next, the plate was washed three times with PBST, and 100 μl of biotinylated rat anti-human IL-6 (working concentration 1:2000) was added per well and left at 37°C for 1 hour. Next, the plate was washed three times with PBST, and the remaining liquid was removed as much as possible with absorbent paper, and 100 μl of streptavidin HRP was added to each well and incubated at room temperature for 1 hour. Then, the plate was washed three times with PBST, and 100 μl of TMB was added to each well and left at room temperature (20±5°C) for 5 minutes in the dark. Next, 50 μl of 2M The reaction of the substrate was stopped by adding H2SO4 stop solution. Then, the OD value was read at 450 nm in the enzyme-linked immunosorbent assay device, and the IL-6 expression level of each well was calculated using the software. Data analysis was performed using Prism6 to generate graphs and calculate IC 50 was calculated.

[0090] The experimental results are shown in Figure 4. The results show that the anti-IL-17 / VEGF bifunctional fusion proteins 17V05 and 17V06 and the positive control 608 monoclonal antibody all inhibited human IL-17A-induced human IL-6 secretion from HeLa cells in a dose-dependent manner. 50 were 0.726, 0.778 and 0.877 nM, respectively, and the bifunctional fusion protein and 608 monoclonal antibody showed equivalent biological activities.

[0091] Example 7 Cellular experiments on the inhibition of VEGF binding to its receptor KDR by anti-IL-17 / VEGF bifunctional fusion protein KDR cells (purchased from Promega, Cat. #GA1082) with a density of about 80-90% in the logarithmic growth phase cultured in a monolayer were taken, and the growth medium was discarded. Next, after washing once with DPBS, the cells were digested with Actase (registered trademark) solution (Sigma, Cat. #A6964), and the pancreatin was neutralized, and then centrifuged at 200 g for 5 minutes. Next, the cells were resuspended using DMEM medium (Gibco, Cat. #11995) containing 10% FBS, and the cells were counted using trypan blue. Then, the cell density was adjusted to 40,000 cells / well, plated, and left at 37°C in 5% CO2 at 50 μl / well. In addition, VEGF was diluted to 30 ng / ml using DMEM medium containing 10% FBS, and the antibody was diluted 2-fold with the medium containing VEGF. This formed a 10-fold gradient with 3-fold dilution. Next, 25 μl of the diluted antibody was added to the cells per well (final VEGF concentration was 10 ng / ml, starting antibody concentration was 100 nM), and after incubation at 37°C for 6 hours, 75 μl of detection reagent Bio-Glo (purchased from Promega, Cat. #G7940) was added to each well. After incubation at room temperature for 10 minutes, the cells were stained with SpectraMax Luminescence was read using an i3x. All data were from duplicate wells, and the signal values ​​were averaged. The data was then fitted using the four-parameter method and analyzed using GraphPad. Data analysis was performed with Prism6.

[0092] The experimental results are shown in Figure 5. Both the anti-IL-17 / VEGF bifunctional fusion protein and the positive control bevacizumab were able to effectively inhibit the interaction between VEGF and its receptor KDR. The inhibitory ability of the bifunctional fusion protein was superior. The IC 50 were 0.072, 0.084, 0.072 and 0.430 nM, respectively.

[0093] Example 8 Physical stability of anti-IL-17 / VEGF bifunctional fusion protein The thermal stability of the anti-IL-17 / VEGF bifunctional fusion protein in a PBS buffer system was measured by DSC (Differential Scanning Calorimetry). The sample was replaced with PBS buffer to control the sample concentration to 1 mg / ml, and the MicroCal*Vp-Capillary was used. Measurements were performed using a DSC (Malvern Instruments). Before the measurement, the samples and blank buffer were filtered through a 0.22 μm membrane filter. Then, 400 μl of sample or blank buffer (six pairs of blank buffers were set up) was added to each well of the sample plate. Finally, ddH2O was added to three sets of microplates for washing. After the samples were added to the sample plate, a soft plastic cover was placed on the plate. The scanning temperature started at 25°C and ended at 100°C. The scanning speed was 150°C / h. The specific results are shown in Table 4. The proteins of samples 17V01, 17V05 and 17V06 all showed good thermal stability.

[0094] [Table 4]

[0095] Example 9 Acceleration and thermostability studies of anti-IL-17 / VEGF bifunctional fusion protein Previous studies have shown that the use of the native D2 domain sequence in a bifunctional fusion protein results in a small amount of breaks in the heavy chain in accelerated and thermal stability studies of several formulations. Therefore, we mutated the methionine at position 138 and examined the accelerated and thermal stability of the modified molecule in formulations.

[0096] The 17V01, 17V05, 17V06 and 17V07 proteins were dissolved in PBS buffer or histidine buffer (L-histidine 0.34mg / ml, histidine hydrochloride monohydrate 1.64mg / ml, arginine hydrochloride 5mg / ml, α,α trehalose dihydrate 50.0mg / ml, polysorbate 80 The protein was concentrated by ultrafiltration to a concentration of 0.01 mg / mL, pH 5.5±0.5) to a protein concentration of 5 to 10 mg / mL. After culturing at 37°C for 4 weeks, a sample was taken and centrifuged, ultrafiltered, and desalted. Next, 100 μg of the protein after ultrafiltration and desalting was taken and diluted with NEB at a concentration of 500,000 U / mL. 1 μl of PNGase F (purchased from NEB, Cat. #P0704L) was added and incubated at 37°C for 2 hours, after which 1M DTT (purchased from Shanghai Synthetic Engineering, Cat. #A620058) was added to a final concentration of 50 mM and incubated at 37°C for 30 minutes. The sample was then diluted with 50 mM NH4HCO3 to a protein concentration of 1.5 mg / ml, mixed uniformly, and centrifuged for 10 minutes (rotation speed ≧12000 rpm). The ACQUITY After separation on a UPLC BEH300 C4 1.7 μm 2.1 × 50 mm chromatography column, the molecular weight of the heavy chain of the fusion protein was determined by mass spectrometry (Waters UPLC-XEVO G2 Q-TOF LC / MS system). As a result, as shown in Table 5, the molecules 17V05, 17V06 and 17V07 were superior in acceleration and thermal stability to the molecule 17V01 using the native D2 domain sequence.

[0097] [Table 5]

[0098] Example 10 Inhibitory effect of anti-IL-17 / VEGF bifunctional fusion protein on laser-induced choroidal neovascularization in mice We induced choroidal neovascularization and leakage in the fundus of mice by laser irradiation, and examined the inhibitory effect of IL-17 / VEGF bifunctional fusion protein on neovascularization and leakage.

[0099] Zoletil (25-50mg / kg, ip) + xylazine hydrochloride injection (5mg / kg, ip) was used to anesthetize 11-12 week old female humanized IL-17 mice (purchased from Baiao Saizu Co., Ltd.). Three laser spots were burned by photocoagulating three points equidistantly around the optic disc at 1.5-2PD from the optic disc using a 532nm laser. After the model was created with the laser, an OCT examination was immediately performed to check for damage to the Bruch's membrane, and any spots without damage to the Bruch's membrane or spots with retinal hemorrhage were removed. On the sixth day (day 6) after the model was created with the laser, an FFA examination was performed and the mice were divided into groups based on the leakage spots that occurred. The anti-IL-17 / VEGF bifunctional fusion protein group was injected with 2 μL of 17V05 (17.49 mg / mL), the aflibercept group was injected with 2 μL of aflibercept (10 mg / mL), and the control group was injected with 2 μL of PBS, so that one intravitreal injection was performed in both eyes. In addition, FFA examination was performed again 7 days after administration (day 14), and CNV leakage in the living mouse was observed using the Heidelberg Spectralis system. In addition, images were taken at the early stage (within 1 minute) and late stage (after 3 minutes), and the fluorescence leakage area was statistically recorded, and the fluorescence leakage status was evaluated and classified into levels (levels I to IV). Level I: No strong fluorescence Level II: Early or mid-stage lesions show high fluorescence but no leakage Level III: Lesions show hyperfluorescence in the early stages and leakage in the later stages Level IV: The lesion shows bright hyperfluorescence in the early stage, and leakage is observed in the later stage and extends beyond the border of the burn area.

[0100] After the test was completed, the animals were euthanized by inhaling large amounts of carbon dioxide and dislocating the cervical spine. The eyeballs of both eyes of the experimental animals were then taken and fixed in 4% PFA at room temperature for 2 hours. The medium was then replaced with pre-cooled PBS, after which the eyeballs were dissected to remove the anterior segment tissue, lens, vitreous body, and retina. The preparations containing RPE / Choroid were retained and subjected to immunofluorescence staining. The test indicator was isolectin B4: Images were taken of each lesion at the same magnification and fluorescence using DAPI, and the CNV area was calculated using ImageJ for statistical analysis.

[0101] Figure 6 shows a comparison between before and after administration 7 days after administration. Regarding the rate of change in vascular leakage area, both IL-17 / VEGF bifunctional fusion protein and aflibercept were able to effectively reduce the leakage area when administered at equimolar concentrations. In addition, the efficacy of IL-17 / VEGF bifunctional fusion protein was superior. Figure 7 shows statistical data on leakage spots of levels 3 to 4. Seven days after administration (day 14), the experimental group administered with IL-17 / VEGF bifunctional fusion protein had a clear reduction in the number of leakage spots of levels 3 to 4 compared to the negative control group. In addition, the effect was superior to that of aflibercept, which is a positive control. Figure 8 shows the measurement of the fundus neovascular area of ​​mice 7 days after administration by performing IB4 immunofluorescence staining after preparing a choroidal preparation. The experimental group administered with IL-17 / VEGF bifunctional fusion protein had a clear reduction in the neovascular area compared to the negative control group. Moreover, its efficacy was superior to that of the positive control, aflibercept.

[0102] To summarize the experimental results, it was found that the IL-17 / VEGF bifunctional fusion protein can effectively inhibit choroidal neovascularization and leakage in the fundus of mice, and its effect is superior to that of the positive control aflibercept.

[0103] The above examples are for illustrating the implementation of the present invention and should not be construed as limiting the present invention. In addition, various modifications and changes to the method of the invention listed in the present specification are obvious to those skilled in the art, provided that they do not deviate from the scope and spirit of the present invention. Although the present invention has been specifically described by combining several specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, any invention obtained by the above modifications that are obvious to those skilled in the art is included in the scope of the present invention.

[0104] [Table 6]

Claims

1. An anti-IL-17 / VEGF bifunctional fusion protein comprising an anti-IL-17 antibody and a protein that specifically binds to VEGF, wherein the protein that specifically binds to VEGF is VEGFR, and the protein that specifically binds to VEGF is linked to the anti-IL-17 antibody directly or via a connexon.

2. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 1, characterized in that the protein that specifically binds to VEGF is the extracellular domain of VEGFR, preferably the protein that specifically binds to VEGF is the extracellular domain of VEGFR1.

3. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 2, wherein the protein that specifically binds to VEGF is the D2 domain of VEGFR1.

4. The heavy chain of the anti-IL-17 antibody comprises complementarity determining regions HCDR1 to 3, the amino acid sequence of HCDR1 being as shown in SEQ ID NO: 14, and the amino acid sequence of HCDR2 being as shown in SEQ ID NO: The amino acid sequence of HCDR3 is as shown in SEQ ID NO:

16. The light chain of the anti-IL-17 antibody comprises complementarity determining regions LCDR1 to LCDR3, and the amino acid sequence of LCDR1 is as shown in SEQ ID NO:

17. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 1, characterized in that the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 17, the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 18, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO:

19.

5. The amino acid sequence of the heavy chain variable region of the anti-IL-17 antibody is shown in SEQ ID NO: 20, and the amino acid sequence of the light chain variable region of the anti-IL-17 antibody is shown in SEQ ID NO: The anti-IL-17 / VEGF bifunctional fusion protein according to claim 1, characterized in that it is as set forth in ID NO:

21.

6. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 1, characterized in that the amino acid sequence of the heavy chain of the anti-IL-17 antibody is as shown in SEQ ID NO: 4, and the amino acid sequence of the light chain is as shown in SEQ ID NO:

1.

7. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 3, wherein the D2 domain of VEGFR1 is wild-type or mutant, and the amino acid sequence of the D2 domain of wild-type VEGFR1 is as shown in SEQ ID NO:

34.

8. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 7, characterized in that the mutant VEGFR1 D2 domain is formed by mutating position 138 of the amino acid sequence shown in SEQ ID NO:

34.

9. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 7, characterized in that the mutant VEGFR1 D2 domain is formed by substitution mutation at position 138 of the amino acid sequence shown in SEQ ID NO:

34.

10. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 7, wherein the mutant of the D2 domain of VEGFR1 is selected from 138M / A, 138M / P, or 138M / T.

11. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 3, wherein the C-terminus or N-terminus of the heavy chain of the anti-IL-17 antibody is linked to the D2 domain of VEGFR1, or the C-terminus or N-terminus of the light chain of the anti-IL-17 antibody is linked to the D2 domain of VEGFR1.

12. The amino acid sequence of the heavy chain of the bifunctional fusion protein is SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: The amino acid sequence of the light chain of the bifunctional fusion protein is as shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO:

10. The anti-IL-17 / VEGF bifunctional fusion protein according to claim 1, characterized in that it is as shown in SEQ ID NO:1, SEQ ID NO:5 or SEQ ID NO:

6.

13. A nucleic acid molecule encoding an anti-IL-17 / VEGF bifunctional fusion protein according to any one of claims 1 to 12.

14. The nucleic acid molecule comprises the nucleic acid sequence SEQ ID NO:25 of the heavy chain of the anti-IL-17 / VEGF bifunctional fusion protein, SEQ ID NO: SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 or SEQ ID NO:33, The nucleic acid molecule of claim 13, which encodes SEQ ID NO: 24, SEQ ID NO: 28 or SEQ ID NO:

29.

15. An expression vector comprising the nucleic acid molecule of claim 13 or 14.

16. A host cell comprising the expression vector of claim 15.

17. A method for producing an anti-IL-17 / VEGF bifunctional fusion protein according to any one of claims 1 to 12, comprising the steps of: a) expressing an anti-IL-17 / VEGF bifunctional fusion protein by culturing the host cell according to claim 16 under expression conditions; b) isolating and purifying the fusion protein of step a); The method according to claim 1, further comprising:

18. A pharmaceutical composition comprising an effective amount of the fusion protein according to any one of claims 1 to 12 and one or more pharma- ceutically acceptable carriers or additives.

19. Use of the anti-IL-17 / VEGF bifunctional fusion protein according to any one of claims 1 to 12 or the pharmaceutical composition according to claim 18 in the manufacture of a medicament for treating a disease in which IL-17 and / or VEGF are overexpressed.

20. Use of the anti-IL-17 / VEGF bifunctional fusion protein according to any one of claims 1 to 12 or the pharmaceutical composition according to claim 18 in the manufacture of a medicament for the treatment of an inflammatory skin disease or an ophthalmological disease, preferably wherein the inflammatory skin disease is psoriasis and / or the ophthalmological disease is selected from diabetic retinopathy, choroidal neovascularization disease or macular degeneration.

21. 1. A method for treating a disease in which IL-17 and / or VEGF is overexpressed, comprising: A method comprising administering to a subject in need thereof a bifunctional fusion protein according to any one of claims 1 to 12 or a pharmaceutical composition according to claim 18.

22. 22. The method of claim 21, wherein the disease overexpressing IL-17 and / or VEGF is selected from an inflammatory skin disease or an ophthalmological disease, preferably the inflammatory skin disease is psoriasis and / or the ophthalmological disease is selected from diabetic retinopathy, choroidal neovascular disease or macular degeneration.